FY21 didn’t turn out too bad for CL Educate. In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. That is not to say it was a rosy FY21 for CL. The global scourge Covid…
Read MoreChemcrux Enterprises suffered only a 7% revenue drop and 17% EBITDA drop in FY21, despite losing over 23% of productive days due to plant closure, and Covid related production constraints in FY21. Highlights of the FY21 results: FY21 full year sales came in at Rs 533m, 7% drop over sales…
Read MoreWe recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…
Read More